1. Date of occurrence of the event: July 27, 2021
2. Company name: OBI Pharma Inc.
3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
4. Reciprocal shareholding ratios: Not applicable
5. Cause of occurrence: OBI Pharma Inc. was informed by the patent agency that patent for OBI-858 “Clostridium botulinum toxin Type A composition, formulation and use thereof” has been granted by the Intellectual Property Office under Patent Number 109110925.
6. Countermeasures: None
7. Any other matters that need to be specified: None